Furthermore, recent research demonstrated that targeting GLP-1 signaling, by GLP-1 agonists or DPP IV inhibitors, may improve intestinal epithelial architecture and reduce inflammatory markers level in mouse models of colitis [9–15]. Here, GLP1R is linked to colitis.